Roche's monoclonal antibody prasinezumab may slow motor deterioration in rapidly progressing Parkinson's disease according to phase 2 trial results.

The treatment showed significant reduction in worsening of motor symptoms at the one-year mark compared to a placebo.

Prasinezumab targets aggregated alpha-synuclein, believed to be a central factor in Parkinson's disease pathology.

The trial's positive outcomes were specifically observed in patients with rapidly progressing Parkinson's, with no significant benefits for slow progressors.

Further studies are required to establish prasinezumab's effectiveness in a broader range of Parkinson's patients and over longer periods.

Current results position prasinezumab as a potential first disease-modifying treatment for Parkinson's, a condition lacking such options to date.

Ongoing research aims to validate these findings in larger patient groups, while the full article with more details is available on the PÚBLICO website.